Further computational prioritization by MitoCareX leads to selection and ordering of molecules for planned experimental assessment Ness Ziona, Israel,, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company") today announced that its wholly owned subsidiary, MitoCareX Bio Ltd.